
Assessing cardiotoxicity of a highly selective novel MCL1 inhibitor with iPSC-derived models

Research highlights: Targeted Protein Degradation in Tauopathies

Case Study: Development of a human iPSC-derived ALS model
-1.png)
The status of drug discovery and development for Parkinson's disease

Uncovering ALS pathology and potential drug targets with in vitro iPSC models
-1.png)
The status of drug discovery and development for Alzheimer's disease